Edition:
United Kingdom

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

62.42USD
8 Dec 2017
Change (% chg)

$0.58 (+0.94%)
Prev Close
$61.84
Open
$61.82
Day's High
$62.70
Day's Low
$61.79
Volume
1,452,263
Avg. Vol
1,482,760
52-wk High
$66.09
52-wk Low
$46.01

Chart for

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $106,283.60
Shares Outstanding(Mil.): 1,639.93
Dividend: 0.39
Yield (%): 2.41

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

Fitch Affirms Allergan's 'BBB-' Rating; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, December 07 (Fitch) Fitch Ratings has affirmed the ratings of Allergan plc (Allergan; NYSE: AGN) and subsidiaries at 'BBB-'. The Rating Outlook is Stable. Fitch has also affirmed and withdrawn the 'BBB-' IDRs of Allergan's subsidiaries, Warner Chilcott Limited and Allergan Finance LLC. These IDRs are no longer considered by Fitch to be relevant to the agency's coverage. A full list of rating actions, which apply to approximatel

07 Dec 2017

BRIEF-Bristol-Myers Squibb Announces 2.6 Pct Increase In Quarterly Dividend Beginning Q1 2018

* BRISTOL-MYERS SQUIBB CO - AN INCREASE OF 2.6% PERCENT IN COMPANY'S QUARTERLY DIVIDEND, BEGINNING IN Q1 OF 2018

07 Dec 2017

BRIEF-Ayala Enters Exclusive Worldwide License Agreement With Bristol-Myers Squibb

* AYALA PHARMACEUTICALS, FOUNDED BY ISRAEL BIOTECH FUND, AMOON AND HAREL INSURANCE, ENTERS EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH BRISTOL-MYERS SQUIBB (BMS) TO DEVELOP CANCER TREATMENTS

06 Dec 2017

BRIEF-European Medicines Agency Validates Bristol-Myers's Type II Variation Application For Opdivo

* EUROPEAN MEDICINES AGENCY VALIDATES BRISTOL-MYERS SQUIBB’S TYPE II VARIATION APPLICATION FOR OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) IN INTERMEDIATE- AND POOR-RISK PATIENTS WITH ADVANCED RENAL CELL CARCINOMA Source text for Eikon: Further company coverage:

28 Nov 2017

Roche win boosts case for adding chemo to cancer immunotherapy

LONDON Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism.

20 Nov 2017

Roche win boosts case for adding chemo to cancer immunotherapy

LONDON, Nov 20 Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism.

20 Nov 2017

BRIEF-Labcorp announces new expanded use for PD-L1 test with Bristol-Myers Squibb's Opdivo

Nov 15 Laboratory Corporation Of America Holdings

15 Nov 2017

BRIEF-Bristol-Myers and Syngene expand ongoing research collaboration

* Bristol-Myers Squibb and Syngene International expand ongoing research collaboration

14 Nov 2017

BRIEF-Syngene International ‍expands collaboration with Bristol-Myers Squibb​

* Nnext phase of partnership will see addition of facility to support future Bristol-Myers Squibb research and development operations​ Source text: http://bit.ly/2iT2tvz Further company coverage:

14 Nov 2017

BRIEF-Bristol-Myers says encouraging response observed with Opdivo plus BMS-986205, in heavily pre-treated patients with advanced cancers in early-stage study

* Encouraging response observed with Opdivo (nivolumab) plus investigational ido1 inhibitor, BMS-986205, in heavily pre-treated patients with advanced cancers in phase 1/2a study ca017-003

10 Nov 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $140.59 +0.58
Pfizer Inc. (PFE.N) $35.74 +0.24
Merck & Co., Inc. (MRK.N) $55.57 +0.80
Sanofi SA (SASY.PA) €73.18 -0.03
AstraZeneca plc (AZN.L) 4,784.00 +79.00
GlaxoSmithKline plc (GSK.L) 1,287.50 +12.00
Eli Lilly and Co (LLY.N) $86.45 +0.58
Roche Holding Ltd. (ROG.S) CHF240.50 -1.80
Roche Holding Ltd. (RO.S) CHF242.50 -1.40

Earnings vs. Estimates